172 related articles for article (PubMed ID: 36102923)
1. Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research.
Langouo Fontsa M; Aiello MM; Migliori E; Scartozzi M; Lambertini M; Willard-Gallo K; Solinas C
Target Oncol; 2022 Sep; 17(5):497-505. PubMed ID: 36102923
[TBL] [Abstract][Full Text] [Related]
2. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors.
Sheng IY; Gupta S; Reddy CA; Angelini D; Funchain P; Sussman TA; Sleiman J; Ornstein MC; McCrae K; Khorana AA
Target Oncol; 2022 Sep; 17(5):563-569. PubMed ID: 35986816
[TBL] [Abstract][Full Text] [Related]
4. Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: A prospective cohort study.
Noumegni SR; Didier R; Mansourati V; Tromeur C; Le Moigne E; Hoffmann C; Nasr B; Gentric JC; Guegan M; Poulhazan E; Lacut K; Bressollette L; Le Mao R; Couturaud F
Thromb Res; 2022 Jun; 214():93-105. PubMed ID: 35525202
[TBL] [Abstract][Full Text] [Related]
5. Assessing the risk of thromboembolism in cancer patients receiving immunotherapy.
Goel A; Khorana A; Kartika T; Gowda S; Tao DL; Thawani R; Shatzel JJ
Eur J Haematol; 2022 Apr; 108(4):271-277. PubMed ID: 34905252
[TBL] [Abstract][Full Text] [Related]
6. Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies.
Moik F; Ay C
Thromb Res; 2022 May; 213 Suppl 1():S58-S65. PubMed ID: 36210562
[TBL] [Abstract][Full Text] [Related]
7. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
8. Venous and Arterial Thromboembolism in Patients with Metastatic Lung Cancer.
Qin Y; Zhang L; Liang X; Sun X; Wang N; Yuan M; Wang Q; Wu D
Clin Appl Thromb Hemost; 2023; 29():10760296231159121. PubMed ID: 36814378
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors.
Ando Y; Hayashi T; Sugimoto R; Nishibe S; Ito K; Kawada K; Ikeda Y; Yamada S; Imaizumi K
Invest New Drugs; 2020 Aug; 38(4):1200-1206. PubMed ID: 31823160
[TBL] [Abstract][Full Text] [Related]
10. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
[TBL] [Abstract][Full Text] [Related]
11. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
[TBL] [Abstract][Full Text] [Related]
12. Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis.
Grilz E; Posch F; Nopp S; Königsbrügge O; Lang IM; Klimek P; Thurner S; Pabinger I; Ay C
Eur Heart J; 2021 Jun; 42(23):2299-2307. PubMed ID: 33769475
[TBL] [Abstract][Full Text] [Related]
13. Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies.
Moik F; Riedl JM; Englisch C; Ay C
Hamostaseologie; 2024 Feb; 44(1):40-48. PubMed ID: 38190985
[TBL] [Abstract][Full Text] [Related]
14. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials.
Ma Z; Sun X; Zhang Y; Li H; Sun D; An Z; Zhang Y
Thromb Haemost; 2022 Oct; 122(10):1757-1766. PubMed ID: 35772727
[TBL] [Abstract][Full Text] [Related]
15. One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry.
Ohashi Y; Ikeda M; Kunitoh H; Sasako M; Okusaka T; Mukai H; Fujiwara K; Nakamura M; Oba MS; Kimura T; Ibusuki K; Takita A; Sakon M
Thromb Res; 2022 May; 213():203-213. PubMed ID: 35282898
[TBL] [Abstract][Full Text] [Related]
16. A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.
Kuderer NM; Culakova E; Lyman GH; Francis C; Falanga A; Khorana AA
Oncologist; 2016 Jul; 21(7):861-7. PubMed ID: 27125754
[TBL] [Abstract][Full Text] [Related]
17. Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
Robertson L; Yeoh SE; Broderick C; Stansby G; Agarwal R
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD010837. PubMed ID: 30407621
[TBL] [Abstract][Full Text] [Related]
18. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
Robertson L; Yeoh SE; Stansby G; Agarwal R
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010837. PubMed ID: 28832905
[TBL] [Abstract][Full Text] [Related]
19. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study.
Mahmoodi BK; ten Kate MK; Waanders F; Veeger NJ; Brouwer JL; Vogt L; Navis G; van der Meer J
Circulation; 2008 Jan; 117(2):224-30. PubMed ID: 18158362
[TBL] [Abstract][Full Text] [Related]
20. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
